# A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Source: https://onco.cc/trials/nct04673942/  
OnCo record `nct04673942` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AdAPT-001 in sarcomas, run by EpicentRx, Inc., active and no longer recruiting.

## Summary

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors is a phase 2 interventional study registered as NCT04673942 by EpicentRx, Inc., with 140 participants enrolled, started 2021-03-29 and due to reach its primary completion in 2026-12-01. Interventions recorded: AdAPT-001 and Checkpoint Inhibitor, Immune.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04673942
- Phase: 2
- Setting: An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
- Sponsor: EpicentRx, Inc.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT04673942: https://clinicaltrials.gov/study/NCT04673942

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [EpicentRx](https://onco.cc/companies/epicentrx/)

---
JSON: https://onco.cc/api/v1/entities/nct04673942.json